Gilead Sciences, Inc. revised earnings guidance for the full year 2022. For the year, the company revised total product sales expectations between $24.5 billion and $25.0 billion, compared to $23.8 billion and $24.3 billion previously, total product sales, excluding Veklury, between $22.0 billion to $22.5 billion, compared to $21.8 billion and $22.3 billion previously and earnings per share between $2.90 and $3.30, compared to $3.00 and $3.50 previously.